Search Patents
-
Patent number: 7452542Abstract: The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.Type: GrantFiled: May 23, 2005Date of Patent: November 18, 2008Assignee: Vanderbilt UniversityInventor: Mark Denison
-
Patent number: 5750112Abstract: This invention provides a vaccine which contains, per dose, an effective immunizing amount of an inactivated feline enteric coronavirus and a suitable carrier. The vaccine of this invention may also contain an adjuvant, an effective immunizing amount of a second inactivated virus and a an effective immunizing amount of an inactivated bacteria. Additionally provided by this invention is a method of immunizing a dog against disease caused by canine coronavirus involving administering to the dog a dose of the vaccine of this invention. The method of this invention may also involve administering one or more additional doses of vaccine to the dog, immunizing the dog against disease caused by a second virus and immunizing the dog against disease caused by a bacteria.Type: GrantFiled: December 8, 1993Date of Patent: May 12, 1998Assignee: Solvay Animal Health, Inc.Inventor: Michael A. Gill
-
Patent number: 5916570Abstract: New purified and isolated bovine coronavirus (BCV) types (II and III) are described which can be used to create new modified live vaccines for administration to cattle in order to confer immunity against virulent wild-type bovine coronavirus infection. Preferably, a multivalent modified live vaccine is provided for oral-nasal administration which includes the known Type I virus and the new Types II and III virus. Hygromycin B has also demonstrated to be effective for suppressing BCV replication and thus can be administered to cattle as a treatment for the chronic disease and to suppress shedding of BCV in cattle feces.Type: GrantFiled: February 4, 1997Date of Patent: June 29, 1999Assignee: Kansas State University Research FoundationInventor: Sanjay Kapil
-
Publication number: 20140205621Abstract: A new pantropic canine coronavirus (CCoV) strain, having reduced pathogenicity, and capable of eliciting an immune response, is described.Type: ApplicationFiled: June 26, 2012Publication date: July 24, 2014Inventors: Nicola Decaro, Vito Martella, Gabriella Elia, Canio Buonavoglia
-
Patent number: 5911999Abstract: A method for preventing canine coronavirus in dogs is disclosed which comprises administering to a dog a live or inactivated vaccine prepared from transmissible gastroenteritis virus of swine (a TGEV vaccine). An inactivated vaccine composition for use in such a method and a process for the manufacture of the inactivated vaccine composition are described.Type: GrantFiled: March 27, 1991Date of Patent: June 15, 1999Assignee: Pfizer, Inc.Inventors: Dale Bordt, Hans Draayer
-
Patent number: 4904468Abstract: A vaccine for protecting canine animals from disease caused by infection with canine corona virus (CCV) which comprises an effective amount of the cell-associated CCV peplomer protein. A polyvalent vaccine comprising an effective amount of cell-associated CCV peplomer protein and an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed.Type: GrantFiled: June 8, 1987Date of Patent: February 27, 1990Assignee: Norden Laboratories, Inc.Inventors: Michael A. Gill, Stephen W. May
-
Patent number: 6974577Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.Type: GrantFiled: February 4, 2001Date of Patent: December 13, 2005Assignee: Novartris AGInventors: Kelly Knape, Stephanie Dykstra, Mary Tinant
-
Publication number: 20150050308Abstract: A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members.Type: ApplicationFiled: August 13, 2014Publication date: February 19, 2015Inventor: Cornelia Maria van der Hoek
-
Patent number: 7309493Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.Type: GrantFiled: August 1, 2005Date of Patent: December 18, 2007Assignee: Novartis AGInventors: Kelly Knape, Stephanie Dykstra, Mary Tinant
-
Patent number: 7618802Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.Type: GrantFiled: January 19, 2006Date of Patent: November 17, 2009Assignee: The University of North Carolina at Chapel HillInventors: Ralph S. Baric, Rhonda Roberts, Boyd Yount, Kristopher M. Curtis
-
Patent number: 7129223Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.Type: GrantFiled: May 19, 2004Date of Patent: October 31, 2006Assignee: The University of HongKongInventors: Hsiang-Fu Kung, Ming-Liang He, Bo-Jiang Zheng, Yi Guan, Marie Chia-Mi Lin, Ying Peng
-
Patent number: 7556957Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutic use, and vaccines derived therefrom. The invention provides replicative coronaviruses and virus-like particles (VLPs) from which large parts of their genome are (at least functionally) deleted without abolishing their replicative capacities. The deletion preferably results in at least a functional deletion in that the corresponding gene is not or is only partly expressed wherein the resulting gene product is dysfunctional or at least functionally distinct from a corresponding wild-type gene product.Type: GrantFiled: November 14, 2003Date of Patent: July 7, 2009Assignees: Stichting voor de Technische Wetenschappen, Universiteit UtrechtInventors: Petrus Josephus Marie Rottier, Cornelis Alexander Maria De Haan, Bert Jan Haijema